title: Are the available low-molecular-weight heparin preparations the same?
abstract: Low molecular weight heparins (LMWHs) are now universally accepted as drugs of choice for post-surgical prophylaxis of DVT. Currently these agents are also being developed for therapeutic and cardiovascular indications. Because of manufacturing differences, each of the LMWHs exhibit distinct pharmacologic and biochemical profiles. The specific activity of these agents in the anticoagulant assays ranges from 35 to 45 anti-IIa U/mg whereas the specific activity in terms of anti-Xa units is designated as 80 to 120 anti-Xa U/mg. These LMWHs are capable of producing product specific dose and time dependent antithrombotic effects in animal models of thrombosis. While the ex vivo effects are initially present at dosages that are antithrombotic, these agents have been found to produce sustained antithrombotic effects without any detectable ex vivo anticoagulant actions. In the experimental animal models and in various clinical trials, these agents have also been found to release tissue factor pathway inhibitor (TFPI) after both intravenous (i.v.) and subcutaneous (s.c.) administration. Repeated administration of LMWHs produces progressively stronger antithrombotic effects; however, the hemorrhagic responses vary and are largely dependent on products. The release of TFPI following i.v. and s.c. administration in a primate model also demonstrated the product individuality and the relevance of this inhibitor to the actions of LMWHs. The effect of repeated administration mimicking the post-surgical prophylaxis of DVT also exhibited product based augmentation of the antithrombotic or hemorrhagic effects. Antithrombotic and hemorrhagic studies are reported that compare the pharmacologic profile of some of the available LMWHs. Product individuality in terms of relative potency in different assays and the failure of standardization protocols to provide any guidelines for product substitution and prediction of the clinical effects is also addressed.
authors.affiliation: Department of Pathology, Loyola University Medical Center, Maywood, IL 60153, USA.
authors.forename: J
authors.initials: J
authors.lastname: Fareed
authors.forename: W
authors.initials: W
authors.lastname: Jeske
authors.forename: D
authors.initials: D
authors.lastname: Hoppensteadt
authors.forename: R
authors.initials: R
authors.lastname: Clarizio
authors.forename: J M
authors.initials: JM
authors.lastname: Walenga
mesh_terms: D000818:Animals; D000925:Anticoagulants / Q000592:standards* / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000592:standards* / Q000627:therapeutic use; D006801:Humans; D011817:Rabbits; D051381:Rats; D017207:Rats, Sprague-Dawley; D013927:Thrombosis / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight